Several states, including Illinois and Louisiana, have passed bills that mandate guideline-recommended or FDA-approved biomarker coverage. The bills vary; some are specific to cancer and some are not.
One of the most recent proposals has been vetoed by the Governor of California, after having been passed by the legislature at the end of August.
The open access news story is available at Genomeweb.
The governor's online rationale is here.
https://www.gov.ca.gov/wp-content/uploads/2022/09/SB-912-VETO.pdf?emrc=49097a
Press release from American Cancer Society here. Univ Calif had supported the bill.
See a related study from ACS in May 2022 regarding patients' access to biomarkers and insurance coverage, here.
See the ACS Cancer Action Network home page of press releases related to access to cancer care here.
See also: https://www.fightcancer.org/state-policy-principles-support-access-biomarker-testing and https://www.fightcancer.org/policy-resources/improving-access-biomarker-testing
